Skip to content
Screener

Pfizer PFE Pfizer CentreOne — Revenues:

Other product segments

Eliquis
$2.43B+21.1%
Vyndaqel family
$1.76B+9.1%
Prevnar Family
$1.69B+1.8%
Ibrance
$1.06B+0.9%
All Other Hospital and Biosimilars
$952M—
All other Primary Care
$699M-5.0%
Padcev
$667M+23.1%
All other Specialty Care
$566M+45.1%
Xtandi
$534M-5.7%
Nurtec ODT/Vydura
$421M+17.3%
Royalty
$396M+28.6%
All other Oncology
$376M-0.3%
Oncology Biosimilars
$359M+1.7%
Lorbrena
$354M+41.0%
Xeljanz
$251M-22.0%
Comirnaty
$232M-58.9%
Braftovi/Mektovi
$223M+22.5%
Inlyta
$218M-10.3%
Abrysvo
$208M+45.5%
Zavicefta (Outside the U.S. and Canada)
$199M+22.1%
Adcetris
$196M-23.1%
Inflectra
$171M—
Orgovyx
$146M—
Enbrel (Outside the U.S. and Canada)
$142M-7.8%
Octagam
$138M—
Tukysa
$138M+4.5%
Sulperazon (Outside the U.S. and Canada)
$116M-30.1%
Bosulif
$113M-24.2%
Zithromax
$112M-29.1%
Cibinqo
$94M+36.2%
Genotropin
$94M-11.3%
Elrexfio
$89M+4.7%
FSME-IMMUN/TicoVac
$81M—
Talzenna
$57M+23.9%
Tivdak
$34M-26.1%
Paxlovid
$21M—

Similar metrics at other companies

SND
SNDSand — Revenues:
$92.49M+43.5%
SND
SNDSmartSystems — Revenues:
$623K-43.1%
SND
SNDCANADA — Revenues:
$17.11M+6,942%
FRP Holdings logo
FRPHDevelopment — Revenues:
$595K+98.3%
FRP Holdings logo
FRPHMultifamily — Revenues:
$5.44M-2.3%
SND
SNDSand Segment — Revenues:
$92.49M+43.5%

Other financials

Income statement

See full
Revenue$15.0B+2.6%
Gross profit$10.9B+0.6%
Net income-$248.0M-109%
EPS (diluted)-$0.04-108%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$147.11B+8.1%
Enterprise value$209.77B+9.2%
P/E16.6×—
P/S2.3×+0.2×

Profitability

See full
Gross margin73.2%+1.1pp
Net margin15.7%—
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Pfizer’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 7:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000078003-26-000054
(MILLIONS) / PRODUCTPRIMARY INDICATION OR CLASSThree Months Ended / March 29,2026Three Months Ended / March 30,2025
All other Specialty CareVarious579486
Hospital and Biosimilars(a)$1,854$1,639
Oncology biosimilars(g)Various409264
Sulperazon (Outside the U.S. and Canada)Bacterial infections199164
InflectraCrohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis182153
ZithromaxBacterial infections112158
All other Hospital and BiosimilarsVarious953901
PFIZER CENTREONE(h)$289$273

Item 1.

FAQ

What is Pfizer's pfizer centreone — revenues:?
Pfizer (PFE) reported pfizer centreone — revenues: of $289M in Q1 2026.
How has Pfizer's pfizer centreone — revenues: changed year-over-year?
Pfizer's pfizer centreone — revenues: increased by 5.9% year-over-year, from $273M to $289M.
What is the long-term trend for Pfizer's pfizer centreone — revenues:?
Over 4 years (2021 to 2025), Pfizer's pfizer centreone — revenues: has grown at a -6.0% compound annual growth rate (CAGR), from $1.73B to $1.35B.
What does pfizer centreone — revenues: mean?
This metric represents the total revenue generated by the Pfizer CentreOne operating segment, which provides contract development and manufacturing organization (CDMO) services. It reflects the income derived from providing specialized pharmaceutical manufacturing and development capabilities to third-party biopharmaceutical companies. This segment serves as a strategic business unit leveraging Pfizer's internal infrastructure to support external partners.

Ask your AI about Pfizer's pfizer centreone — revenues:.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude